<DOC>
	<DOCNO>NCT00304018</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy , fludarabine , busulfan , etoposide , donor umbilical cord blood stem cell transplant help stop growth cancer cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Giving antithymocyte globulin transplant tacrolimus prednisone transplant may stop happen . PURPOSE : This phase I trial study well donor umbilical cord blood transplant work treat patient advanced hematologic cancer .</brief_summary>
	<brief_title>Donor Umbilical Cord Blood Transplant Treating Patients With Advanced Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety feasibility perform donor umbilical cord blood transplantation ( UCBT ) patient advance hematologic malignancy , term &gt; 80 % engraftment rate day 100 post-transplant ≤ 50 % transplant-related mortality . Secondary - Determine toxicity myeloablative preparative regimen comprise busulfan , fludarabine , etoposide prior UCBT patient . - Determine neutrophil platelet recovery patient treat regimen . - Determine event-free overall survival patient treat regimen . - Evaluate lineage-specific chimerism UCBT ass contribution individual cord blood unit post-transplantation hematopoiesis patient . - Determine incidence , severity , time acute chronic graft-vs-host disease patient treat regimen . OUTLINE : This pilot study . - Preparative regimen : Patients receive fludarabine IV 30 minute day -7 -3 , busulfan IV 2 hour 4 time daily day -7 -4 , etoposide IV 4 hour day -3 , anti-thymocyte globulin IV 6 hour day -2 -1 . - Donor umbilical cord blood transplantation ( UCBT ) : Patients undergo donor UCBT day 0 . Beginning day 7 , patient receive sargramostim ( GM-CSF ) IV subcutaneously daily blood count recover . - Graft-vs-host disease prophylaxis : Patients receive tacrolimus IV continuously 24 hour orally twice daily begin day -2 continue day 180 follow taper . Patients also receive oral prednisone twice daily day 13-50 daily day 50-60 , follow rapid taper . After completion study treatment , patient follow periodically approximately 2 year . PROJECTED ACCRUAL : A total 10 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 follow advanced hematologic malignancy : Acute myeloid leukemia ( AML ) meeting follow criterion : Not expect curable chemotherapy meet ≥ 1 follow criterion : Highrisk cytogenetics ( 7 , 7q , 5 , 5q , [ 6,9 ] , [ 9,11 ] , complex , Philadelphia chromosome positive [ Ph+ ] ) AML evolve prior myelodysplasia AML secondary prior chemotherapy Failed achieve remission In second subsequent remission Marrow blast ≤ 10 % ( may achieve use chemotherapy ) Myelodysplastic syndrome ( MDS ) highrisk feature International Prognostic Scoring System ( IPSS ) score intermediate 2 highrisk Marrow blast ≤ 20 % ( may achieve use chemotherapy ) Acute lymphoblastic leukemia meeting follow criterion : Not expect curable chemotherapy meet ≥ 1 follow criterion : Highrisk cytogenetics ( Ph+ , [ 4,11 ] , 11q23 abnormality , monosomy 7 ) Required &gt; 1 induction course achieve remission Failed achieve remission In second subsequent remission Marrow blast ≤ 10 % ( may achieve use chemotherapy ) Chronic myelogenous leukemia meeting ≥ 1 follow criterion : Accelerated phase Chronic phase refractory imatinib mesylate Blastic phase Marrow blast ≤ 10 % ( may achieve use chemotherapy ) Multiple myeloma meeting 1 follow criterion : Stage II III disease &gt; first relapse refractory disease Newly diagnose disease chromosome 13 abnormality Lymphoma meeting follow criterion : One follow subtypes : Diffuse large cell lymphoma Mantle cell lymphoma Peripheral Tcell lymphoma Tnatural killer ( NK ) cell lymphoma Hodgkin 's lymphoma Disease fail respond primary therapy , progress , recur prior therapy Patients fail autologous stem cell transplantation eligible provide &gt; 1 year since transplant No rapid progression malignant disease Not eligible autologous stem cell transplantation Available umbilical cord blood ( 13 unit ) donor match ≥ 4 6 HLA antigen ( A , B , DR ) Patients HLAidentical 1 antigenmismatched related donor OR potential HLAmatched unrelated donor match &gt; 6/8 ( A , B , C , DR ) alleles eligible PATIENT CHARACTERISTICS : ECOG performance status 02 Creatinine &lt; 2.0 mg/dL Creatinine clearance &gt; 40 mL/min Bilirubin &lt; 2.0 mg/dL AST alkaline phosphatase &lt; 3 time upper limit normal Hepatitis C active hepatitis B allow patient ≤ grade 2 inflammation fibrosis liver biopsy Ejection fraction &gt; 40 % echocardiogram MUGA DLCO &gt; 40 % predict Not pregnant nursing Negative pregnancy test No know HIV infection No active infection require ongoing antibiotic treatment PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute erythroid leukemia ( M6 )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage I multiple myeloma</keyword>
</DOC>